Haemonetics Q3 2025: Unpacking Contradictions in Plasma Growth, VASCADE Performance, and CSL Impact

These are the key contradictions discussed in Haemonetics Corporation's latest 2025 Q3 earnings call, specifically including: Plasma Collection Growth Expectations, VASCADE Product Performance, and CSL Contribution:



Revenue Growth and Earnings Expansion:
- Haemonetics Corporation reported third-quarter revenue of $349 million, showing a 4% increase on a reported basis but flat organically.
- Earnings per share were up 14% to $1.19. This growth was attributed to strong performance in the hospital segment and a focus on higher-margin opportunities.

Plasma Segment Dynamics:
- Plasma revenue declined 9% in the third quarter, primarily due to the planned CSL divestiture and a 5% decline year-to-date.
- The decline was also driven by a temporary pullback in plasma collections and ongoing market disruptions, but the company expects to recover to historical growth rates with new technology and customer adoption strategies.

Hospital Segment Leadership:
- The hospital segment experienced 24% revenue growth on a reported basis, with organic growth of 12% in the third quarter.
- Growth was driven by strong performance in Blood Management Technologies, Hemostasis management, transfusion management, and Interventional Technologies, particularly in electrophysiology procedures.

Plasma Collection Technology Innovation:
- Haemonetics made progress in transitioning customers to its NexSys and Persona technologies, expecting these upgrades to substantially complete by the end of the fiscal year.
- The company's innovation, enabling cost reduction and improved donor safety, is enhancing market share and margin expansion in the plasma collections business.